- Investing Ideas
- U.S. Pharmaceuticals & Biotech Healthy potentially undervalued
U.S. Pharmaceuticals & Biotech Healthy potentially undervalued
Results
86
Companies which are potentially undervalued and in an acceptable financial position.
86 companies
Arcutis Biotherapeutics
Market Cap: US$3.6b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$27.74
7D
7.5%
1Y
84.8%
CorMedix
Market Cap: US$680.2m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$8.40
7D
-4.0%
1Y
-25.1%
Regeneron Pharmaceuticals
Market Cap: US$68.0b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
REGN
US$664.52
7D
1.6%
1Y
17.0%
Elanco Animal Health
Market Cap: US$12.3b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$24.82
7D
-0.7%
1Y
66.6%
Supernus Pharmaceuticals
Market Cap: US$2.8b
A biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
SUPN
US$48.46
7D
0.9%
1Y
46.3%
Collegium Pharmaceutical
Market Cap: US$1.2b
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$35.23
7D
-4.9%
1Y
8.3%
Ardelyx
Market Cap: US$1.3b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.28
7D
0.2%
1Y
17.6%
Fennec Pharmaceuticals
Market Cap: US$358.1m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$10.49
7D
-2.0%
1Y
19.5%
Tarsus Pharmaceuticals
Market Cap: US$2.8b
A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
TARS
US$58.14
7D
-11.2%
1Y
48.4%
Journey Medical
Market Cap: US$192.7m
A commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$6.91
7D
-2.5%
1Y
-3.4%
Exagen
Market Cap: US$111.6m
Designs, develops, and commercializes various testing products under the AVISE brand in the United States.
XGN
US$4.45
7D
-2.0%
1Y
-36.3%
Perrigo
Market Cap: US$1.4b
Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.
PRGO
US$10.22
7D
-7.3%
1Y
-62.9%
Abeona Therapeutics
Market Cap: US$405.8m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$6.98
7D
9.1%
1Y
21.6%
Vanda Pharmaceuticals
Market Cap: US$383.7m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$6.24
7D
0.5%
1Y
31.6%
Verastem
Market Cap: US$474.5m
A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
VSTM
US$5.53
7D
22.9%
1Y
18.0%
Madrigal Pharmaceuticals
Market Cap: US$12.9b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$536.70
7D
1.6%
1Y
70.1%
Viatris
Market Cap: US$19.0b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$16.27
7D
-2.6%
1Y
78.4%
Trulieve Cannabis
Market Cap: US$1.7b
Operates as a cannabis retailer in the United States.
TRLV
US$8.62
7D
-11.9%
1Y
88.2%
Amphastar Pharmaceuticals
Market Cap: US$838.6m
A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
AMPH
US$18.72
7D
-4.7%
1Y
-13.6%
TG Therapeutics
Market Cap: US$8.4b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$57.12
7D
7.1%
1Y
54.0%
ACADIA Pharmaceuticals
Market Cap: US$4.5b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$26.22
7D
1.0%
1Y
25.0%
Pacira BioSciences
Market Cap: US$1.0b
Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
PCRX
US$25.48
7D
0.4%
1Y
11.3%
Zevra Therapeutics
Market Cap: US$824.1m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$13.35
7D
-4.5%
1Y
6.5%
Exelixis
Market Cap: US$14.4b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$56.50
7D
1.2%
1Y
25.9%
ADMA Biologics
Market Cap: US$2.1b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$9.08
7D
1.5%
1Y
-50.9%
Protara Therapeutics
Market Cap: US$242.8m
A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
TARA
US$4.32
7D
6.4%
1Y
41.6%
United Therapeutics
Market Cap: US$23.5b
Engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
UTHR
US$547.06
7D
-1.6%
1Y
85.1%
Theravance Biopharma
Market Cap: US$880.0m
A biopharmaceutical company, develops and commercializes medicines in the United States.
TBPH
US$16.93
7D
0%
1Y
49.8%
CareDx
Market Cap: US$1.5b
Provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
CDNA
US$28.51
7D
-2.3%
1Y
41.6%
Caris Life Sciences
Market Cap: US$4.8b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$16.99
7D
-7.2%
1Y
-35.9%
Assembly Biosciences
Market Cap: US$552.3m
A biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
ASMB
US$27.40
7D
-1.2%
1Y
46.1%
Phibro Animal Health
Market Cap: US$1.3b
Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.
PAHC
US$32.07
7D
-3.6%
1Y
4.1%
Innoviva
Market Cap: US$1.6b
Operates as a biopharmaceutical company in the United States and internationally.
INVA
US$22.24
7D
-0.3%
1Y
18.5%
Verrica Pharmaceuticals
Market Cap: US$112.2m
A dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
VRCA
US$6.26
7D
2.0%
1Y
-22.4%
Coherus Oncology
Market Cap: US$251.4m
A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
CHRS
US$1.54
7D
6.2%
1Y
75.0%
Bruker
Market Cap: US$9.1b
Develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions.
BRKR
US$60.06
7D
-2.6%
1Y
37.2%